DNA repair and personalized breast cancer therapy

Environmental and Molecular Mutagenesis

Volumn 51, Issue 8-9, 2010, Pages 897-908

  Li, Shu Xia ^a   Sjolund, Ashley ^b   Harris, Lyndsay ^c   Sweasy, Joann B ^b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

Breast cancer; Cancer; DNA repair; Personalized gene therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC METAL COMPLEX; BIOLOGICAL MARKER; BRCA1 PROTEIN; DNA; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TAXANE DERIVATIVE;

BREAST CANCER; CANCER CLASSIFICATION; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DNA ADDUCT; DNA CROSS LINKING; DNA MICROARRAY; DNA REPAIR; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; EXCISION REPAIR; FANCONI ANEMIA; HUMAN; HYPOTHESIS; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; PHENOTYPE; REVIEW; TREATMENT RESPONSE; XERODERMA PIGMENTOSUM; BREAST TUMOR; CLASSIFICATION; DNA FINGERPRINTING; FEMALE; GENETICS; PERSONALIZED MEDICINE;

BREAST NEOPLASMS; DNA FINGERPRINTING; DNA REPAIR; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 78349233047     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20606     Document Type: Review

References (109)

1. Adams CP, Brantner VV. 2006. Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 25: 420-428.
2. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB. 1994. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α-pseudomonas exotoxin 40 fusion protein. Cancer Res 54: 4703-4709.
3. Audebert M, Salles B, Calsou P. 2004. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 279: 55117-55126.
4. Barnes DE, Lindahl T. 2004. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38: 445-476.
5. Beger C, Ramadani M, Meyer S, Leder G, Kruger M, Welte K, Gansauge F, Beger HG. 2004. Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. Clin Cancer Res 10: 3780-3787.
6. Bell DW. 2010. Our changing view of the genomic landscape of cancer. J Pathol 220: 231-243.
7. Bergstralh DT, Sekelsky J. 2008. Interstrand crosslink repair: Can XPF-ERCC1 be let off the hook? Trends Genet 24: 70-76.
8. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. 2005. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65: 11597-11604.
9. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
10. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod SA. 2009. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115: 359-363.
11. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisnowski R, Slolek M, Narod SA, Lubinski J. 2010. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant therapy. J Clin Oncol 28: 375-379.
12. Caldecott KW. 2008. Single-strand break repair and genetic disease. Nat Rev Genet 9: 619-631.
13. Chaires JB, Dattagupta N, Crothers DM. 1982. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: Equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry 21: 3933-3940.
14. Chaires JB, Dattagupta N, Crothers DM. 1983. Binding of daunomycin to calf thymus nucleosomes. Biochemistry 22: 284-292.
15. Chaires JB, Dattagupta N, Crothers DM. 1985. Kinetics of the daunomycin-DNA interaction. Biochemistry 24: 260-267.
16. Chaires JB, Fox KR, Herrera JE, Britt M, Waring MJ. 1987. Site and sequence specificity of the daunomycin-DNA interaction. Biochemistry 26: 8227-8236.
17. Chaires JB, Herrera J, Britt M, Fox KR, Waring MJ. 1988. Sequence specificity of the daunomycin-DNA interaction. Biochem Pharmacol 37: 1785-1786.
18. Chaires JB, Herrera JE, Waring MJ. 1990. Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. Biochemistry 29: 6145-6153.
19. Chang P, Jacobson MK, Mitchison TJ. 2004. Poly(ADP-ribose) is required for spindle assembly and structure. Nature 432: 645-649.
20. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A. 2000. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11: 1057-1059.
21. Dawlaty M, Malureanu L, Jeganathan K, Sustmann C, Tahk S, Shuai K, FGrosschedl R, van Deursen J. 2008. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase II α. Cell 133: 103-115.
22. Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L. 2007. Using specific cytotoxics with a targeted mind. Breast 16: S120-S126.
23. Ding SL, Sheu LF, Yu JC, Yang TL, Chen BF, Leu FJ, Shen CY. 2004. Abnormality of the DNA double-strand-break checkpoint/repair genes ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer 90: 1995-2001.
24. Druker BJ. 2002. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8(4 Suppl ): S14-S18.
25. Dupuy A, Simon RM. 2007. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157.
26. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
27. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
28. Fortini P, Dogliotti E. 2007. Base damage and single-strand break repair: Mechanisms and functional significance of short- and long-patch repair subpathways. DNA Repair (Amst) 6: 398-409.
29. Frank R, Hargreaves R. 2003. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-580.
30. Frei E, 3rd. 1972. Combination cancer therapy: Presidential address. Cancer Res 32: 2593-2607.
31. Freidberg EC, Wood RD, Walker GC, Siede W. 2006. DNA Repair and Mutagen. Washington, DC: ASM Press.
32. Fritzsche H, Triebel H, Chaires JB, Dattagupta N, Crothers DM. 1982. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: Geometry of intercalation of iremycin and daunomycin. Biochemistry 21: 3940-3946.
33. Fritzsche H, Wahnert U, Chaires JB, Dattagupta N, Schlessinger FB, Crothers DM. 1987. Anthracycline antibiotics. Interaction with DNA, nucleosomes and inhibition of DNA synthesis. Biochemistry 26: 1996-2000.
34. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122.
35. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. 2008. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100: 14-20.
36. George SL. 2008. Statistical issues in translational cancer research. Clin Cancer Res 14: 5954-5958.
37. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. 2001. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979-5984.
38. Guidance for Industry Pharamcogenomic Data. 2005. UDS DHHS, FDA, CDER, CBER, CDRH.
39. Hanaka T, Cao Y, Bergstrom D, Kooperberg C, Tapscott S, Yao M-C. 2007. Intrastrand annealing leads to the formation of a large DNA plaindrome and determines the boundaries of genomic amplification in human cancer. Mol Cell Biol 27: 1993-2002.
40. Hanawalt PC, Spivak G. 2008. Transcription-coupled DNA repair: Two decades of progress and surprises. Nat Rev Mol Cell Biol 9: 958-970.
41. Harris L, Parker J, Broadwater G, Schulz V, Halligan K, Lezon-Geyda K, Seidman A, Berry D, Winer E, Hudis C, Krasnitz A, Hicks J, Tuck D, Perou C. 2009. Genome-Wide Profiling of Archived Material from CALGB 9840 and 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. In Proceedings of the CTRC-AACR San Antonio Breast Cancer Symposiusm; San Antonio, TX. Philadelphia, PA: AACR. Abstract nr 4032.
42. Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS. 2001. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 7: 1497-1504.
43. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellsi MJ, Berry D. 2007. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496-1506.
44. Hu F, Rosenberg WF. 2006. The theory of response-adaptive reandomization in clinical trials. Hoboken, NJ: Wiley-Interscience.
45. Huber A, Bai P, de Murcia JM, de Murcia G. 2004. PARP-1, PARP-2 and ATM in the DNA damage response: Functional synergy in mouse development. DNA Repair (Amst) 3: 1103-1108.
46. Jarvin T, Tanner M, Barlund M, Borg A, Isola J. 1999. Characterization of topoisomerase IIa gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26: 142-150.
47. Jaspers JE, Rottenberg S, Jonkers J. 2009. Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim Biophys Acta 1796: 266-280.
48. Jiang W, Freidlin B, Simon R. 2007. Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 99: 1036-1043.
49. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, Jr., O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. 2006. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-A plan to move forward. Clin Cancer Res 12: 3661-3697.
50. +-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119: 803-814.
51. Kinsella T. 2009. Understanding DNA damage response and DNA repair pathways: Applications to more targeted cancer therapeutics. Semin Oncol 36: S42-S51.
52. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670.
53. Lang T, Dalal S, Chikova A, DiMaio D, Sweasy JB. 2007. The E295K DNA polymerase beta gastric cancer-associated variant interferes with base excision repair and induces cellular transformation. Mol Cell Biol 27: 5587-5596.
54. Luo K, Yuan J, Chen JG, Lou Z. 2009. Topoisomerase II α controls the decatenation chekcpoint. Nat Cell Biol 11: 204-210.
55. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM. 1996. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465.
56. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, Mackay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB, Sager R. 2000. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res 60: 2232-2238.
57. Martin LP, Hamilton TC, Schilder RJ. 2008a. Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 14: 1291-1295.
58. Martin SA, Lord CJ, Ashworth A. 2008b. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18: 80-86.
59. McCabe KM, Olson SB, Moses RE. 2009. DNA interstrand crosslink repair in mammalian cells. J Cell Physiol 220: 569-573.
60. McElhinny SAN, Havener JM, Garcia-Diaz M, Juarez R, Bebenek K, Kee BL, Blanco L, Kunkel TA, Ramsden DA. 2005. A gradient of template dependence defines distinct biological roles for family X polymerases in nonhomologous end joining. Mol Cell 19: 357-366.
61. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. 2005. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
62. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS. 1995. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9: 439-443.
63. Moore JK, Haber JE. 1996. Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol Cell Biol 16: 2164-2173.
64. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C. 2009. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol (Meeting Abstr) 27(18S): 3.
65. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators. 2006. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991.
66. Olopade O, Grushko T, Nanda R, Huo D. 2008. Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 14: 7988-7999.
67. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
68. Pardo B, Gomez-Gonzalez B, Aguilera A. 2009. DNA repair in mammalian cells: DNA double-strand break repair: How to fix a broken relationship. Cell Mol Life Sci 66: 1039-1056.
69. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
70. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406: 747-752.
71. Powell SN, Bindra RS. 2009. Targeting the DNA damage response for cancer therapy. DNA Repair (Amst) 8: 1153-1165.
72. Rabbani A, Finn RM, Ausio J. 2005. The anthracycline antibiotics: Antitumor drugs that alter chromatin structure. Bioessays 27: 50-56.
73. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CEJr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
74. Saffi J, Agnoletto MH, Guecheva TN, Batista LF, Carvalho H, Henriques JA, Stary A, Menck CF, Sarasin A. 2009. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells. DNA Repair (Amst) 9: 40-47.
75. San Filippo J, Sung P, Klein H. 2008. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77: 229-257.
76. Sawyers CL. 2008. The cancer biomarker problem. Nature 452: 548-552.
77. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. 2008. Triple-negative breast cancer: Risk factors to potential targets. Clin Cancer Res 14: 8010-8018.
78. Shall S, de Murcia G. 2000. Poly(ADP-ribose) polymerase-1: What have we learned from the deficient mouse model? Mutat Res 460: 1-15.
79. Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, Liotta L, Petricoin EF, Pierobon M. 2010. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010: 1-10.
80. Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Samara R, Espinoza LA, Hassa PO, Hottiger MO, Smulson ME. 2003. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase. Oncogene 22: 8460-8471.
81. Simon R. 2008. The use of genomics in clinical trial design. Clin Cancer Res 14: 5984-5993.
82. Simon R, Wang SJ. 2006. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenom J 6: 166-173.
83. Singer E. 2005. Personalized medicine prompts push to redesign clinical trials. Nat Med 11: 462.
84. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. 2008. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19: 1847-1852.
85. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
86. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423.
87. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398.
88. Sudo T, Nitta M, Saya H, Ueno NT. 2004. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508.
89. Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z, Downward J. 2009. Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 106: 8671-8676.
90. Sweasy JB, Dalal S, Sun KW, Lai C-C, DiMaio D, Lang T. 2005. Expression of DNA polymerase beta mutants in mouse cells results in cellular transformation. Proc Natl Acad Sci USA 102: 14350-14355.
91. Sweasy JB, Lang T, DiMaio D. 2006. Is base excision repair a tumor suppressor mechanism? Cell Cycle 5: 250-259.
92. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P. 2009. Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. Cancer J 15: 406-420.
93. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. 2007. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 67: 7078-7081.
94. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J. 2009. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (Meeting Abstr) 27(18S): CRA501.
95. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
96. Venkitaraman AR. 2002. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
97. Venkitararman AR. 2009. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol Mech Dis 4: 461-487.
98. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS. 2003. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006-2011.
99. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
100. Wang AH, Gao YG, Liaw YC, Li YK. 1991. Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry 30: 3812-3815.
101. Wang D, Lippard SJ. 2005. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
102. Wang SJ, O'Neill RT, Hung HM. 2007. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 6: 227-244.
103. Weaver BA, Cleveland DW. 2005. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8: 7-12.
104. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JAJr, Marks JR, Nevins JR. 2001. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98: 11462-11467.
105. Wiederhold L, Leppard JB, Kedar P, Karimi-Busheri F, Rasouli-Nia A, Weinfeld M, Tomkinson AE, Izumi T, Prasad R, Wilson SH, Mitra S, Hazra TK. 2004. AP endonuclease-independent DNA base excision repair in human cells. Mol Cell 15: 209-220.
106. Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. 1999. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21: 236-240.
107. Wilson TE, Grawunder U, Lieber MR. 1997. Yeast DNA ligase IV mediates non-homologous DNA end joining. Nature 388: 495-498.
108. Yager JD, Davidson NE. 2006. Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
109. Zeman SM, Phillips DR, Crothers DM. 1998. Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci USA 95: 11561-11565.